{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:39:34Z","timestamp":1790127574938,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Clinics of North America"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ucl.2026.02.009","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:54:27Z","timestamp":1773816867000},"page":"263-272","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic Treatments in Men with De Novo Metastatic Prostate Cancer"],"prefix":"10.1016","volume":"53","author":[{"given":"Dong-Hoon","family":"Lim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac Yi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ucl.2026.02.009_bib1","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.009_bib2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1158\/1055-9965.EPI-22-1038","article-title":"Estimating the number of men living with metastatic prostate cancer in the United States","volume":"32","author":"Devasia","year":"2023","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"14","key":"10.1016\/j.ucl.2026.02.009_bib3","doi-asserted-by":"crossref","first-page":"2931","DOI":"10.1002\/cncr.31384","article-title":"Trends in incidence and 5-year mortality in men with newly diagnosed, metastatic prostate cancer-A population-based analysis of 2 national cohorts","volume":"124","author":"Helgstrand","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ucl.2026.02.009_bib4","article-title":"Characterization of Differences Between Prostate Cancer Patients Presenting With De Novo Versus Primary Progressive Metastatic Disease","author":"Finianos","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.009_bib5","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/JU.0000000000001375","article-title":"Advanced prostate cancer: AUA\/ASTRO\/SUO guideline PART I","volume":"205","author":"Lowrance","year":"2021","journal-title":"J Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.009_bib6","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1056\/NEJMoa1603144","article-title":"Inherited DNA-repair gene mutations in men with metastatic prostate cancer","volume":"375","author":"Pritchard","year":"2016","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.009_bib7","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/s41391-021-00430-4","article-title":"Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer","volume":"25","author":"Velez","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.009_bib8","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.3390\/curroncol31020078","article-title":"Contemporary systemic therapy intensification for prostate cancer: a review for general practitioners in oncology","volume":"31","author":"Batra","year":"2024","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.009_bib9","doi-asserted-by":"crossref","first-page":"769","DOI":"10.5534\/wjmh.220200","article-title":"Systemic therapies for metastatic castration-resistant prostate cancer: an updated review","volume":"41","author":"Hatano","year":"2023","journal-title":"World J Mens Health"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.009_bib10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/JU.0000000000001376","article-title":"Advanced prostate cancer: AUA\/ASTRO\/SUO guideline PART II","volume":"205","author":"Lowrance","year":"2021","journal-title":"J Urol"},{"issue":"20","key":"10.1016\/j.ucl.2026.02.009_bib11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15204945","article-title":"De Novo Metastatic Prostate Cancer: are We Moving toward a Personalized Treatment?","volume":"15","author":"Piombino","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.ucl.2026.02.009_bib12","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer","volume":"378","author":"Sartor","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.ucl.2026.02.009_bib13","doi-asserted-by":"crossref","first-page":"7909","DOI":"10.1002\/cam4.4074","article-title":"Marginal improvement in survival among patients diagnosed with metastatic prostate cancer in the second-line antiandrogen therapy era","volume":"10","author":"Kim","year":"2021","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.009_bib14","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nrurol.2016.26","article-title":"Current use of PSMA-PET in prostate cancer management","volume":"13","author":"Maurer","year":"2016","journal-title":"Nat Rev Urol"},{"issue":"11","key":"10.1016\/j.ucl.2026.02.009_bib15","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.009_bib16","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.009_bib17","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.009_bib18","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.009_bib19","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.009_bib20","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0022-5347(05)64820-3","article-title":"Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941","volume":"168","author":"Huggins","year":"2002","journal-title":"J Urol"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.009_bib21","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/JU.0000000000002757","article-title":"Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management","volume":"208","author":"Eastham","year":"2022","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.009_bib22","first-page":"235","article-title":"The medical research council prostate cancer working party investigators group","volume":"79","year":"1997","journal-title":"Br J Urol"},{"issue":"6","key":"10.1016\/j.ucl.2026.02.009_bib23","article-title":"Early versus deferred standard androgen suppression therapy for advanced hormone-sensitive prostate cancer","volume":"6","author":"Kunath","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.009_bib24","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","article-title":"Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.009_bib25","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1464-410X.2008.08062.x","article-title":"Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy","volume":"103","author":"Morote","year":"2009","journal-title":"BJU Int"},{"issue":"11 Pt B","key":"10.1016\/j.ucl.2026.02.009_bib26","first-page":"E500","article-title":"Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?","volume":"110","author":"Pickles","year":"2012","journal-title":"BJU Int"},{"issue":"3","key":"10.1016\/j.ucl.2026.02.009_bib27","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/JU.0000000000000809","article-title":"Testosterone breakthrough rates during androgen deprivation therapy for castration sensitive prostate cancer","volume":"204","author":"Saad","year":"2020","journal-title":"J Urol"},{"issue":"15","key":"10.1016\/j.ucl.2026.02.009_bib28","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.009_bib29","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ucl.2026.02.009_bib30","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10024","key":"10.1016\/j.ucl.2026.02.009_bib31","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.009_bib32","article-title":"Taxane-based chemohormonal therapy for metastatic hormone-sensitive prostate cancer","volume":"10","author":"Sathianathen","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.009_bib33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/S1470-2045(12)70560-0","article-title":"Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial","volume":"14","author":"Gravis","year":"2013","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.009_bib34","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"10336","key":"10.1016\/j.ucl.2026.02.009_bib35","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 x 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.009_bib36","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","article-title":"Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer","volume":"90","author":"O'Donnell","year":"2004","journal-title":"Br J Cancer"},{"issue":"7560","key":"10.1016\/j.ucl.2026.02.009_bib37","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1038\/nature14406","article-title":"Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer","volume":"523","author":"Li","year":"2015","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.009_bib38","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1634\/theoncologist.2014-0167","article-title":"Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer","volume":"19","author":"Auchus","year":"2014","journal-title":"Oncologist"},{"issue":"5928","key":"10.1016\/j.ucl.2026.02.009_bib39","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1126\/science.1168175","article-title":"Development of a second-generation antiandrogen for treatment of advanced prostate cancer","volume":"324","author":"Tran","year":"2009","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.009_bib40","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.009_bib41","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J Natl Compr Cancer Netw"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.009_bib42","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/jamaoncol.2023.0324","article-title":"Triplet therapy in metastatic hormone-sensitive prostate cancer\u2014calling out the \u201cDouble Standard\u201d","volume":"9","author":"McHugh","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ucl.2026.02.009_bib43","doi-asserted-by":"crossref","first-page":"S655","DOI":"10.1016\/j.annonc.2021.08.1129","article-title":"616P real-world utilization of advanced therapies by metastatic site and age among patients with metastatic castration-sensitive prostate cancer (mCSPC): a medicare database analysis","volume":"32","author":"George","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ucl.2026.02.009_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.08.007","article-title":"Treatment trajectories in metastatic hormone-sensitive prostate cancer: a PIONEER+ big data analysis","author":"Nicoletti","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"7381","key":"10.1016\/j.ucl.2026.02.009_bib45","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/nature10760","article-title":"The DNA damage response and cancer therapy","volume":"481","author":"Lord","year":"2012","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.ucl.2026.02.009_bib46","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1002\/em.22087","article-title":"Mechanisms of DNA damage, repair, and mutagenesis","volume":"58","author":"Chatterjee","year":"2017","journal-title":"Environ Mol Mutagen"},{"issue":"1\u20132","key":"10.1016\/j.ucl.2026.02.009_bib47","first-page":"131","article-title":"Homologous recombinational repair of DNA ensures Mammalian chromosome stability","volume":"477","author":"Thompson","year":"2001","journal-title":"Mutat Res"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.009_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23010348","article-title":"Homologous recombination deficiencies and hereditary tumors","volume":"23","author":"Yamamoto","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ucl.2026.02.009_bib49","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1162644","article-title":"Impact of DNA damage repair alterations on prostate cancer progression and metastasis","volume":"13","author":"Lukashchuk","year":"2023","journal-title":"Front Oncol"},{"issue":"19","key":"10.1016\/j.ucl.2026.02.009_bib50","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1158\/1078-0432.CCR-25-1178","article-title":"Association of homologous recombination repair alterations with outcomes in patients with metastatic hormone-sensitive prostate cancer","volume":"31","author":"Hage Chehade","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.009_bib51","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/s41391-023-00676-0","article-title":"Guidelines for genetic testing in prostate cancer: a scoping review","volume":"27","author":"Tuffaha","year":"2024","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7035","key":"10.1016\/j.ucl.2026.02.009_bib52","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/nature03443","article-title":"Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase","volume":"434","author":"Bryant","year":"2005","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.ucl.2026.02.009_bib53","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrg.2017.47","article-title":"Synthetic lethality and cancer","volume":"18","author":"O'Neil","year":"2017","journal-title":"Nat Rev Genet"},{"issue":"22","key":"10.1016\/j.ucl.2026.02.009_bib54","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1911440","article-title":"Olaparib for metastatic castration-resistant prostate cancer","volume":"382","author":"de Bono","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ucl.2026.02.009_bib55","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician\u2019s choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.009_bib56","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.ucl.2026.02.009_bib57","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.euo.2025.04.012","article-title":"Niraparib and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: final overall survival analysis for the phase 3 MAGNITUDE trial","volume":"8","author":"Chi","year":"2025","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.ucl.2026.02.009_bib58","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-025-03961-8","article-title":"Niraparib and abiraterone acetate plus prednisone for HRR-deficient metastatic castration-sensitive prostate cancer: a randomized phase 3 trial","author":"Attard","year":"2025","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ucl.2026.02.009_bib59","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","article-title":"Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer","volume":"22","author":"Bakht","year":"2025","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.ucl.2026.02.009_bib60","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-med-062117-073027","article-title":"Imaging of prostate-specific membrane antigen with small-molecule PET radiotracers: from the bench to advanced clinical applications","volume":"70","author":"Rowe","year":"2019","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.ucl.2026.02.009_bib61","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1148\/radiol.2021202771","article-title":"Prostate-specific membrane antigen PET in prostate cancer","volume":"299","author":"Lawhn-Heath","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.ucl.2026.02.009_bib62","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3389\/fonc.2018.00623","article-title":"Expression of prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis","volume":"8","author":"Hupe","year":"2018","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.ucl.2026.02.009_bib63","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ucl.2026.02.009_bib64","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: Lutetium Lu 177 vipivotide Tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ucl.2026.02.009_bib65","doi-asserted-by":"crossref","unstructured":"Tagawa ST, Sartor O, Piulats JM, et al. Esmo 2025: phase III trial of [177Lu]Lu-PSMA-617 combined with ADT + ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition). UroToday, Available at: https:\/\/www.urotoday.com\/conference-highlights\/esmo-2025\/esmo-2025-prostate-cancer\/164097-esmo-2025-phase-iii-trial-of-177lu-lu-psma-617-combined-with-adt-arpi-in-patients-with-psma-positive-metastatic-hormone-sensitive-prostate-cancer-psmaddition.html (Accessed 14 November 2025), 2025.","DOI":"10.1016\/j.annonc.2025.09.101"}],"container-title":["Urologic Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000091?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0094014326000091?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T17:22:25Z","timestamp":1776446545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0094014326000091"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0094014326000091"],"URL":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.009","relation":{},"ISSN":["0094-0143"],"issn-type":[{"value":"0094-0143","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Treatments in Men with De Novo Metastatic Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ucl.2026.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}